Delaware v. Big Pharma | Delaware Business

The Delaware Department of Justice announced on Wednesday, January 14, 2026, that a lawsuit has been filed in the Court of Chancery against the nation’s three primary insulin manufacturers, and the three largest pharmacy benefit managers.

Delaware Attorney General Kathy Jennings claims Eli Lilly, Novo Nordisk, and Sanofi-Aventis, along with CVS Caremark, Express Scripts, and OptumRx, conspired to increase insulin prices by as much as 1,000 percent over the past fifteen years.

She said their actions violate the state’s Consumer Fraud Act and the Deceptive Trade Practices Act.

“The level of greed that would drive someone to price-gouge consumers over life-saving diabetes medicine is almost unfathomable,” said Jennings in a prepared statement. “It is an avarice that not only hurts diabetics across the country financially, but in many cases leads to medication hoarding and preventable deaths. The thousands of Delawareans living with diabetes need to know that we will hold these companies accountable.”

Jennings office says 112,000 Delawareans live with diabetes, and another 130,000 are pre-diabetic, with an estimated economic impact of $1.1 billion a year.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source